Updates are available Correction dated 2022-10-14
Click to view Correction: https://doi.org/10.1038/s43018-022-00458-y
-
Authors
Deng, Su
Wang, Choushi http://orcid.org/0000-0002-6667-1689
Wang, Yunguan
Xu, Yaru
Li, Xiaoling
Johnson, Nickolas A.
Mukherji, Atreyi
Lo, U-Ging
Xu, Lingfan
Gonzalez, Julisa
Metang, Lauren A.
Ye, Jianfeng
Tirado, Carla Rodriguez
Rodarte, Kathia
Zhou, Yinglu
Xie, Zhiqun http://orcid.org/0000-0001-7163-7242
Arana, Carlos
Annamalai, Valli
Liu, Xihui http://orcid.org/0000-0002-9716-1032
Vander Griend, Donald J. http://orcid.org/0000-0003-4421-5698
Strand, Douglas http://orcid.org/0000-0002-0746-927X
Hsieh, Jer-Tsong
Li, Bo http://orcid.org/0000-0002-8617-900X
Raj, Ganesh http://orcid.org/0000-0001-5098-6347
Wang, Tao http://orcid.org/0000-0002-4355-149X
Mu, Ping http://orcid.org/0000-0003-0955-0896
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH2110418, W81XWH-16-1-0474, W81XWH18-1-0411, W81XWH21-1-0520)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32C124334, R01CA178431, 1R01CA245318, 1R01CA258584, 1P30CA142543, 5R00CA218885, 1R37CA258730)
Cancer Prevention and Research Institute of Texas (RP160157, RR170079, RP190208, RR170050, RP220473)
Welch Foundation (I-2005-20190330)
Prostate Cancer Foundation (17YOUN12)
University of Texas Southwestern Medical Center (Endowed Scholar, Cancer Center Pilot)
- License Information
-
More Information
Article History
Received: 30 January 2022
Accepted: 2 August 2022
First Online: 5 September 2022
Change Date: 14 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-022-00458-y
Competing interests
: G.R. holds issued and pending patents, which have been licensed to EtiraRx. G.R. serves or has served in an advisory role to Bayer, Johnson and Johnson, Myovant, EtiraRx, Amgen, Pfizer and Astellas. G.R. has or has had grant support from Bayer, EtiraRx and Johnson and Johnson. All other authors declare that they have no competing interests.
